Ascendis Pharma A/S filed a Form 6-K on November 12, 2026, disclosing that its board of directors granted 28,030 warrants to certain employees on November 10, 2026, at an exercise price of US $256.59 per share.

Key Highlights

  • Grant date: November 10, 2026, as approved by the company's board of directors.
  • Warrants granted: An aggregate of 28,030 warrants were issued to certain employees of the company.
  • Exercise price: US $256.59 per share, equal to the closing price of the company's ordinary shares on the date of grant, according to the filing.
  • Vesting schedule: 25% vests on the one-year anniversary of the grant date, with the remaining 75% vesting at a rate of 1/36th per month thereafter, subject to continued service.
  • Remaining warrant pool: After this grant, warrants to subscribe for 1,431,143 additional shares remain available for future grant under the company's Articles of Association.
  • Articles of Association amended: The company amended its Articles of Association in connection with the grant to provide for the issuance of these warrants.

Ascendis Pharma Employee Warrant Grant Details: November 2026

Ascendis Pharma A/S (NASDAQ:ASND), a Danish biopharmaceutical company headquartered in Hellerup, Denmark, disclosed through a Form 6-K filed November 12, 2026, that its board of directors approved a warrant grant to certain employees on November 10, 2026. According to the filing, an aggregate of 28,030 warrants were granted under the terms of Appendix 1a to the company's Articles of Association. Each warrant confers the right to subscribe for one ordinary share of the company.

The filing states that the exercise price was set at US $256.59 per share, described as "the closing price of the Company's ordinary shares as reported on the date of grant." The vesting terms provide that 25% of the warrants will vest on the one-year anniversary of the grant date, with the remaining 75% vesting at a rate of 1/36th per month beginning one year after the grant date, in each case subject to continued service. The filing also notes that earlier vesting may occur upon the occurrence of certain exit events.

In connection with this grant, the company disclosed that it amended its Articles of Association to provide for the issuance of these warrants. The filing noted that after giving effect to this grant, warrants to subscribe for an additional 1,431,143 shares remain available for future grant by the board of directors pursuant to the Articles of Association. The filing was signed by Michael Wolff Jensen, Executive Vice President and Chief Legal Officer of Ascendis Pharma A/S.

What Was Disclosed

Ascendis Pharma A/S reported a board-approved grant of 28,030 employee warrants on November 10, 2026, at US $256.59 per share, with a standard four-year vesting schedule and 1,431,143 warrants remaining available for future issuance.